The intrauterine device: how to deploy this strategy in the molecular world?
Clin Cancer Res
; 2024 Sep 10.
Article
em En
| MEDLINE
| ID: mdl-39254401
ABSTRACT
Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or Grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article